9:00 a.m.  
Welcome and Opening Remarks  
Alan Weil, Editor in Chief, Health Affairs

9:10 a.m.  
Panel 1: Pharmaceuticals and Biotechnology  
Ernest Berndt, Louis E. Seley Professor in Applied Economics, Massachusetts Institute of Technology, on Sharp Decline In Economic Returns From New Drugs Raises Questions About Sustaining Innovations  
Kevin Outterson, Professor of Law and Professor of Health Law, Bioethics & Human Rights, Boston University School of Law, on Repairing The Broken Market For Antibiotic Innovation  
Aaron Kesselheim, Associate Professor of Medicine, Harvard Medical School, on The Roles Of Academia, Rare Diseases, And Repurposing In The Development Of The Most Transformative Drugs  
Gregory Daniel, Managing Director for Evidence Development & Innovation, Engelberg Center for Health Care Reform, Brookings Institution, on Improving Pharmaceutical Innovation By Building A More Comprehensive Database On Drug Development And Use  
Ronald Evens, Adjunct Research Professor, Tufts Center for the Study of Drug Development, on The Evolution Of Biotechnology And Its Impact On Health Care

10:10 a.m.  
Panel 2: Medical Devices  
Amitabh Chandra, Professor of Public Policy and Director of Health Policy Research, Harvard Kennedy School of Government, on Robot-Assisted Surgery For Kidney Cancer Increased Access To A Procedure That Can Reduce Mortality And Renal Failure  
Jeffrey C. Lerner, President and CEO, ECRI Institute, on Analysis Of Health Technology Forecasts Suggest Frequent Revisions Could Improve Accuracy  
John Carroll, Professor of Medicine, Division of Cardiology, Medical Director of the Cardiac and Vascular Center, University of Colorado School of Medicine, on Transcatheter Valve Therapy Replacement Registry Is A Model For Medical Device Innovation And Surveillance

10:50 a.m.  
Break

11:00 a.m.  
Panel 3: Accelerating and Diffusing Innovation  
David Asch, Professor of Medicine, Medical Ethics and Health Policy, Anesthesiology and Critical Care Medicine, Health Care Management, and Operations and Information Management, Wharton School, University of
Pennsylvania, on *Creating Value In Health By Understanding And Overcoming Resistance To De-Innovation*

**Henry Grabowski**, Professor of Economics and Director, Program in Pharmaceuticals and Health Economics, Duke University, on *The Roles Of Patents And Research And Development Incentives In Biopharmaceutical Innovation*

**Suzann Pershing**, Assistant Professor of Ophthalmology, Stanford University School of Medicine, and Chief of Ophthalmology, VA Palo Alto Health Care System, on *Treating Age-Related Macular Degeneration: Comparing The Use Of Two Drugs Among Medicare And Veterans Affairs Populations*

11:30 a.m.

**Panel 4: Financing Innovation**

**Benjamin Falit**, Clinical Fellow in Radiation Oncology, Brigham and Women’s Hospital, on *Biosimilar Competition In The United States: Statutory Incentives, Payers, And Pharmacy Benefit Managers*

**James Chambers**, Assistant Professor of Medicine, Tufts Medical Center Institute for Clinical Research and Health Policy Studies, on *Medicare Is Scrutinizing Evidence More Tightly For National Coverage Determinations*

**James C. Robinson**, Leonard D. Schaeffer Professor of Health Economics; Chair, Berkeley Center for Health Technology; and Head, Division of Health Policy & Management, University of California Berkeley School of Public Health, on *Biomedical Innovation In The Era Of Health Care Spending Constraints*

**John Hernandez**, Vice President, Health Economics and Outcomes Research Abbott Vascular, on *US Hospital Payment Adjustments For Innovative Technology Lag Behind Those In France, Germany, And Japan*

**Jonathan Fleming**, President and Treasurer, Network for Excellence in Health Innovation, on *The Decline Of Venture Capital Investment In Early-Stage Life Sciences Poses A Challenge To Continued Innovation*

12:30 p.m.

**Adjourn**